Webinar Setterwalls and VILDA: Shareholders’ Agreements – Key Considerations for Life Sciences

On 23 september, we at Setterwalls invite you to a seminar on key considerations for shareholders’ agreements in life sciences companies. The seminar will provide practical insights into the issues that founders, investors and companies should consider when structuring, negotiating and implementing shareholders’ agreements in the life sciences sector. Do not miss this opportunity to gain a better understanding of how a well-drafted shareholders’ agreement can help support long-term growth, manage investor and founder expectations, and reduce the risk of future disputes.

Setterwalls and VILDA strengthen female leaders in life sciences through strategic networking and business law expertise.

Briefly about shareholders’ agreements in life sciences companies
Shareholders’ agreements play a central role in regulating the relationship between founders, investors and other shareholders. For life sciences companies, these agreements often need to address sector-specific considerations, including long development timelines, significant funding needs, regulatory milestones, intellectual property rights, collaboration arrangements and exit strategies.

A carefully structured shareholders’ agreement can provide clarity on governance, financing, ownership, transfer restrictions, decision-making and shareholder rights. It can also help align the interests of key stakeholders during different stages of the company’s development, from early-stage research and development to clinical trials, commercial partnerships and potential exits.

Can a shareholders’ agreement affect your company’s development?
For life sciences companies, the shareholders’ agreement is often more than a standard corporate document. It can have a significant impact on the company’s ability to raise capital, attract strategic partners, retain key founders and employees, and prepare for future transactions. Understanding the key provisions and common negotiation points is therefore important for companies, founders and investors alike.

Agenda

• Shareholders’ agreements in a life sciences context
• Governance and decision-making
• Financing obligations and future funding rounds
• Transfer restrictions, exit rights and liquidity events
• Intellectual property and founder considerations
• Common negotiation points and practical insights

This seminar is aimed at founders, board members, CEOs, in-house counsel, investors and other key stakeholders in life sciences companies who are involved in ownership, financing, governance or strategic transactions. It will also be relevant for companies preparing for investment rounds, collaborations, exits or other situations where shareholder alignment is critical.

Practical information:

• Date: 23 September 2026
• Time: 12.00-13.00
• The webinar will be held in English and is free of charge. You do not need to be a member of the VILDA network to participate.

Please register via the link below. If you have any questions in advance, you are welcome to contact us and you may find our contact details below.

A warm welcome – we look forward to seeing you!

Setterwalls Advokatbyrå and the VILDA network are partnering to strengthen female leadership, ownership and innovation within the life sciences sector. By combining strategic networking with commercial legal expertise, we are creating the conditions for sustainable growth, sound corporate governance and better opportunities to funding. In 2026, Setterwalls holds this series of webinars to the community and other leaders within the life sciences industry. Read more about VILDA here.